Cephalon's boss brought Provigil to market, runs his biotech like a Big Pharma, and mouths off at you-know-who. Now he's going global with plans to corner cancer. The really scary thing is, Baldino, 53, hasn't even peaked.
The practiced modesty may be new—and not his native style—but the substance is old-school Baldino. Although predictions in
pharma are folly, with Cephalon stock and strategy stronger than ever, no one should be surprised to see its boss still playing
at the big table—placing bets and winning—in another 20 years.
This online version incorporates corrections made in the printed version.